Which of the following receptors does not span the cell membrane 7 times a. β-Adrenergic receptor b. Rhodopsin c. 5-HTic receptor d. Mineralocorticoid receptor

Which of the following receptors does not span the cell membrane 7 times
a. β-Adrenergic receptor
b. Rhodopsin
c. 5-HTic receptor
d. Mineralocorticoid receptor
by

1 Answer

Answer :

Mineralocorticoid receptor
by

Related questions

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Norepinephrine binds mainly to (A) α-Adrenergic receptors (B) β-Adrenergic receptrors (C) Muscarinic receptors (D) Nicotinic receptors

Description : Norepinephrine binds mainly to (A) α-Adrenergic receptors (B) β-Adrenergic receptrors (C) Muscarinic receptors (D) Nicotinic receptors

Last Answer : Answer : A

Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Description : Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Last Answer : Answer : D

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Most hormone receptors are localized on the cell membrane and transduce hormone binding into altered levels of intracellular messengers. A limited number of intracellular receptors do exist. Which of the following statement(s) is/are true concerning intracellular receptors? a. The messengers or hormones must by lipophilic b. These intracellular receptors generally regulate protein synthesis c. The intracellular receptors are located entirely in the nucleus of the cell d. A heat-shock protein serves as an inhibitor protein blocking the DNA-binding domain of the steroid receptor

Description : Most hormone receptors are localized on the cell membrane and transduce hormone binding into altered levels of intracellular messengers. A limited number of intracellular receptors do exist. Which of ... protein serves as an inhibitor protein blocking the DNA-binding domain of the steroid receptor

Last Answer : Answer: a, d Although most hormone and other messenger receptors are extracellular, intracellular receptors have been identified. The hormone messengers involved for these receptors are primarily ... DNA-binding domain of the receptor. Activation involves the dissociation of the inhibitor protein

Which of the following statement(s) is/are true concerning cell membrane receptors? a. The largest family of cell surface receptors are the G-protein-linked receptors b. Activities of the G-protein involve binding and hydrolysis of ATP c. The G protein receptor generates an intracellular messenger commonly through the use adenylate cyclase d. Tyrosine kinase receptors are considered G-protein-linked receptors

Description : Which of the following statement(s) is/are true concerning cell membrane receptors? a. The largest family of cell surface receptors are the G-protein-linked receptors b. Activities of the ... through the use adenylate cyclase d. Tyrosine kinase receptors are considered G-protein-linked receptors

Last Answer : Answer: a, c All water-soluble regulatory molecules bind to the cell surface receptor proteins. Binding of the appropriate ligand evokes an intracellular signal which usually regulates ... are adenylate cyclase, which converts ATP to cAMP, and the polyphosphoinositide-specific phospholipase C

β-Subunits of insulin receptor are present (A) Outside the cell membrane (B) In the cell membrane (C) Across the cell membrane (D) In the cytosol

Description : β-Subunits of insulin receptor are present (A) Outside the cell membrane (B) In the cell membrane (C) Across the cell membrane (D) In the cytosol

Last Answer : Answer : C

What is correct to say about the hormone action in humans? (a) Glucagon is secreted by β-cells of islets of Langerhans and stimulates glycogenolysis. (b) Secretion of thymosins is stimulated with aging. (c) In females, FSH first binds with specific receptors on ovarian cell membrane. (d) FSH stimulates the secretion of estrogen and progesterone.

Description : What is correct to say about the hormone action in humans? (a) Glucagon is secreted by β-cells of islets of Langerhans and stimulates glycogenolysis. (b) Secretion of thymosins is stimulated ... receptors on ovarian cell membrane. (d) FSH stimulates the secretion of estrogen and progesterone.

Last Answer : (c) In females, FSH first binds with specific receptors on ovarian cell membrane.

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Following potassium sparing diuretic is a mineralocorticoid receptor antagonist (a) Amiloride (b) Triamterene (c) Spironolactone (d) All of the above

Description : Following potassium sparing diuretic is a mineralocorticoid receptor antagonist (a) Amiloride (b) Triamterene (c) Spironolactone (d) All of the above

Last Answer : Ans: C

The only correct statement about hormone receptors is (A) Receptors for protein hormones are present in cytosol (B) Receptors for steroid hormones are membrane bound (C) Hormone-receptor binding is irreversible (D) Receptors can undergo down regulation and up regulatoin

Description : The only correct statement about hormone receptors is (A) Receptors for protein hormones are present in cytosol (B) Receptors for steroid hormones are membrane bound (C) Hormone-receptor binding is irreversible (D) Receptors can undergo down regulation and up regulatoin

Last Answer : Answer : D

Clonal selection includes a. Antigen-receptor binding on B cells. b. Antibody secretion recognizing same epitope as on B cell receptors. c. Differentiation of B cells into plasma cells and memory cells. d. All the above (A—C) are correct.

Description : Clonal selection includes a. Antigen-receptor binding on B cells. b. Antibody secretion recognizing same epitope as on B cell receptors. c. Differentiation of B cells into plasma cells and memory cells. d. All the above (A—C) are correct.

Last Answer : d. All the above (A—C) are correct.

Which statement is NOT true about steroid hormones? A) They include hormones such as estrogen. B) They do not bind to cell surface receptors. C) The hormone-receptor complex can enter the nucleus. D) The hormone-receptor complex can bind to chromatin. E) Steroid hormones act faster than non-steroid (peptide) hormones.

Description : Which statement is NOT true about steroid hormones? A) They include hormones such as estrogen. B) They do not bind to cell surface receptors. C) The hormone-receptor complex can enter the ... complex can bind to chromatin. E) Steroid hormones act faster than non-steroid (peptide) hormones.

Last Answer : E) Steroid hormones act faster than non-steroid (peptide) hormones.

Rod cells possess a trans-membrane protein which is (A) Adenylate cyclase (B) Transducin (C) Rhodopsin (D) B as well as C

Description : Rod cells possess a trans-membrane protein which is (A) Adenylate cyclase (B) Transducin (C) Rhodopsin (D) B as well as C

Last Answer : Answer : C

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Variable regions are present in (A) Immunoglobulins (B) α-Chains of T cell receptors (C) β-Chains of T cell receptors (D) All of these

Description : Variable regions are present in (A) Immunoglobulins (B) α-Chains of T cell receptors (C) β-Chains of T cell receptors (D) All of these

Last Answer : Answer : D

Choose the correct statement from the following about a1 – adrenergic receptor agonists (a) Norepinephrine > isoproterenol > epinephrine (b) Norepinephrine < epinephrine > isoproterenol (c) Epinephrine = norepinephrine >> isoproterenol (d) Epinephrine > isoproterenol > norepinephrine

Description : Choose the correct statement from the following about a1 – adrenergic receptor agonists (a) Norepinephrine > isoproterenol > epinephrine (b) Norepinephrine < epinephrine > isoproterenol (c) Epinephrine = norepinephrine >> isoproterenol (d) Epinephrine > isoproterenol > norepinephrine

Last Answer : Ans: C

Select the correct statement from the following about a1 – adrenergic receptor agonists (a) Isoproterenol > epinephrine = norepinephrine (b) Epinephrine > isoproterenol > norepinephrine (c) Isoproterenol = epinephrine = norepinephrine (d) Epinephrine = norepinephrine > isoproterenol

Description : Select the correct statement from the following about a1 – adrenergic receptor agonists (a) Isoproterenol > epinephrine = norepinephrine (b) Epinephrine > isoproterenol > norepinephrine (c) Isoproterenol = epinephrine = norepinephrine (d) Epinephrine = norepinephrine > isoproterenol

Last Answer : Ans: A

Drugs that block the a receptor on effector cells at adrenergic nerve endings (a) Antagonize the effects of isoproterenol on the heart rate (b) Antagonize some of the effects of epinephrine on the blood pressure (c) Antagonize the effects of epinephrine on adenylyl cyclase (d) Cause mydriasis (e) Decreases blood glucose levels

Description : Drugs that block the a receptor on effector cells at adrenergic nerve endings (a) Antagonize the effects of isoproterenol on the heart rate (b) Antagonize some of the effects of epinephrine on ... the effects of epinephrine on adenylyl cyclase (d) Cause mydriasis (e) Decreases blood glucose levels

Last Answer : Ans: B

At the adrenergic synapse, the concentration of adrenaline in synaptic cleft: a. increased by cocaine which inhibit reuptake of adrenaline b. decreased by MAO (monoamine oxidase) - inhibitors c. controlled chiefly by the activity of the enzyme COMT d. increased by noradrenaline receptor blockers

Description : At the adrenergic synapse, the concentration of adrenaline in synaptic cleft: a. increased by cocaine which inhibit reuptake of adrenaline b. decreased by MAO (monoamine oxidase) - inhibitors c. controlled chiefly by the activity of the enzyme COMT d. increased by noradrenaline receptor blockers

Last Answer : increased by cocaine which inhibit reuptake of adrenaline

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

The following receptor has an intrinsic ion channel: A. Histamine H1 receptor B. Histamine H2 receptor C. Adrenergic alfa receptor D. GABA-benzodiazepine receptor

Description : The following receptor has an intrinsic ion channel: A. Histamine H1 receptor B. Histamine H2 receptor C. Adrenergic alfa receptor D. GABA-benzodiazepine receptor

Last Answer : D. GABA-benzodiazepine receptor

The following receptor has an intrinsic ion channel: A. Histamine H1 receptor B. Histamine H2 receptor C. Adrenergic alfa receptor D. GABA-benzodiazepine receptor

Description : The following receptor has an intrinsic ion channel: A. Histamine H1 receptor B. Histamine H2 receptor C. Adrenergic alfa receptor D. GABA-benzodiazepine receptor

Last Answer : D. GABA-benzodiazepine receptor

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

Binding of catecholamines to α2− adrenergic receptors (A) Increases the intracellular concentration of cAMP (B) Increases the intracellular concentration of cGMP (C) Decreases the intracellular concentration of cAMP (D) Decreases the intracellular concentration of cGMP

Description : Binding of catecholamines to α2− adrenergic receptors (A) Increases the intracellular concentration of cAMP (B) Increases the intracellular concentration of cGMP (C) Decreases the intracellular concentration of cAMP (D) Decreases the intracellular concentration of cGMP

Last Answer : Answer : C

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

a2–adrenergic receptors are associated with following except (a) Increase in phospholipase C activity (b) Increase in potassium channel conductance (c) Decrease in calcium channel conductance (d) Increase in adenylyl cyclase activity

Description : a2–adrenergic receptors are associated with following except (a) Increase in phospholipase C activity (b) Increase in potassium channel conductance (c) Decrease in calcium channel conductance (d) Increase in adenylyl cyclase activity

Last Answer : Ans: D

Improvement of memory in Alzheimer's disease is brought about by drugs which increase transmission in (A) cholinergic receptors (B) dopaminergic receptors (C) GABAergic receptors (D) adrenergic receptors

Description : Improvement of memory in Alzheimer's disease is brought about by drugs which increase transmission in (A) cholinergic receptors (B) dopaminergic receptors (C) GABAergic receptors (D) adrenergic receptors

Last Answer : (A) cholinergic receptors

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Last Answer : D. Diuretics

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Description : The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Last Answer : A. They are added to conventional therapy after cardiac compensation is restored

Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Description : Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Last Answer : D. Alfa adrenergic agonist

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium

In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Description : In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Last Answer : D. Both B and C are correct

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity